logo Creation made simple
Beautifully designed
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut convallis tempor orci vitae vehicula. Aliquam in ullamcorper lacus.
Follow & share
Infallible Pharma | FLIPATRA INJECTION
portfolio_page-template-default,single,single-portfolio_page,postid-20934,edgt-core-1.0.1,ajax_fade,page_not_loaded,,hudson-ver-1.8, vertical_menu_with_scroll,smooth_scroll,side_menu_slide_from_right,blog_installed,wpb-js-composer js-comp-ver-5.0.1,vc_responsive



Brand Name : Flipatra

Generic Name : Atracurium Besylate Injection IP

Pack Size : 5 x 2.5 ml Ampule & 5 x 5 ml Ampule

Dosage Form : Solution for Injection

Strength : 10 mg/ml

Therapeutic indications : Atracurium Besylate Injection is indicated as an adjunct to general anaesthesia during surgery to relax skeletal muscles, and to facilitate endotracheal intubation and mechanical ventilation. It is also indicated to facilitate mechanical ventilation in intensive care unit (ICU) patients.

Pharmacotherapeutic group : non-depolarising neuromuscular blocking agent

ATC code : M03A C04

Pharmacodynamic properties : Atracurium besylate is a non-depolarising neuromuscular blocking agent with an intermediate duration of action, administered intravenously to produce skeletal muscle relaxation.
Non-depolarising neuromuscular blocking agents antagonise the action of the neurotransmitter acetylcholine by competitively binding with cholinergic receptor sites on the motor endplate of the myoneural junction. These effects may be inhibited or reversed by the administration of anticholinesterases such as neostigmine or pyridostigmine.
As with other non-depolarising neuromuscular blocking agents, the time to onset or paralysis is reduced, and the duration of maximum effect prolonged, with increasing atracurium doses.


February 12, 2022